Shanghai: Monday, October 18, 2010: Hutchison MediPharma today announces that it is a winner is selected one of the Deloitte Touche Tohmatsu’s ranking of top 50 fast-growing technology companies in Hong Kong and on the Chinese Mainland by Deloitte Touche Tohmatsu, the business advisory firm.
The “Deloitte Technology Fast 50 China 2010 program” is a yearly ranking of strong growth technology companies by Deloitte, the business advisory firm. This 2010 program is the 6th anniversary of the highly reputable industry platform, with significant credibility as a benchmark for identifying strong performing technology companies.
Hutchison MediPharma willis invited to attend thean award presentation ceremony to be held on October 22, 2010 in Shanghai, followed by a CEO forum on the same day for mutual discussions of topical industry issues. In addition, the Company will be admitted to participate in the Deloitte Technology Fast 500 Asia Pacific 2010 program, which annually recognizes the 500 fastest growing technology companies in Asia Pacific.
About Deloitte Technology Fast 50 China 2010 Program
Inaugurated in 2005, the Deloitte Technology Fast 50 China Program ranks the three-year average revenue growth rates of technology companies headquartered on the Chinese Mainland or in Hong Kong. Together with the technology fast programs in Australia, Japan, South Korea and New Zealand, the Deloitte Technology Fast 50 China Program is part of the Deloitte Technology Fast 500 Asia Pacific Program, which is reputed as one of the most established and objective ranking programs of fast-growing technology companies in the Asia Pacific Region.
For more details about the Deloitte Technology Fast 50 China 2010 program, please visit www.deloitte.com/cn/techfast50.
About Hutchison MediPharma
Hutchison MediPharma is a leading biotechnology company in China. The Company has a team of well over 200 scientists and staff focusing on discovery and development of botanical drugs, semi-synthetic natural product drugs, and synthetic single chemical entity drugs. Hutchison MediPharma has a pipeline of single new chemical entity projects in both oncology and auto-immune/inflammatory disease.
Hutchison MediPharma Limited
Building 4, 720 Cai Lun Road
Zhangjiang Hi-Tech Park
Shanghai, China 201203